Skin as a surrogate tissue for pharmacodynamic end points: Is it deep enough?

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2389-2390

  Baselga, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BIOLOGICAL MARKER; CANERTINIB; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; KI 67 ANTIGEN; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; TRASTUZUMAB;

BREAST TUMOR; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HUMAN; IN VIVO STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN; TISSUE; TUMOR BIOPSY; TUMOR GROWTH;

CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SKIN PHYSIOLOGY;

EID: 0038493878     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Rothenberg, M. L., Carbone, D. P., and Johnson, D. H. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat. Rev. Cancer, 3: 303-309, 2003.
2. Dancey, J., and Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov., 2: 296-313, 2003.
3. Lewis, G. D., Figari, I., Fendly, B., Wong, W. L., Carter, P., Gorman, C., and Shepard, H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37: 255-263, 1993.
4. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neuoverexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
5. Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., and Slamon, D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancers. Oncogene, 18: 2241-2251, 1999.
6. Albanell, J., Codony-Servat, J., Rojo, F., Del Campo, J. M., Sauleda, S., Raspall, G., Giralt, J., Roselló, J., Nicholson, R. I., Mendelsohn, J., and Baselga, J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-EGF receptor treatments. Cancer Res., 61: 6500-6510, 2001.
7. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R. I., and Baselga, J. Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 ('Iressa') in Skin from cancer patients: histopathological and molecular consequences of receptor inhibition. J. Clin. Oncol., 20: 110-124, 2002.
8. Stoll, S., Benedict, M., Mitra, R., Hiniker, A., Elder, J. T., and Nunez, G. EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL. Oncogene, 16: 1493-1499, 1998.
9. Jost, M., Kari, C., and Rodeck, U. The EGF receptor: an essential regulator of multiple epidermal functions. Eur. J. Dermatol., 10: 505-510, 2000.
10. Malik, S. N., Siu, L. L., Rowinsky, E. K., deGraffenried, L., Hammond, L. A., Rizzo, J., Bacus, S., Brattain, M. G., Kreisberg, J. I., and Hidalgo, M. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res., 9: 2478-2486, 2003.
11. Hoeskstra, R. D. H. A Phase I and pharmacological study of intermittent dosing of PKI 166, a novel EGFR tyrosine kinase inhibitor administered orally to patients with advanced cancer. In: AACR-NCI-EORTC 2001.
12. Zinner, R. G., Nemunaitis, J. J., Donato, N. J., Shin, H. C., Myers, J. N., Zhang, P. S., Zentgraft, R. E., Lee, J. J., Khuri, F. R., Glisson, B. S., Eiseman, I., Olson, S. C., Bycott, P., Lenehan, P. F., Hong, W. K., and Shin, D. M. A Phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors. In: Proceedings AACR-NCI-EORTC, Molecular targets and cancer therapeutics, Miami, FL, p. 566, 2001.
13. Tabernero, J., Rojo, F., Jimenez, E., Montaner, I., Santome, L., Guix, M., Rosen, Kovar, A., Viaplana, I., and Baselga, J. A Phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR. Eur. J. Cancer, 38 (Suppl. 7): 69, 2002.
14. Vivanco, I., and Sawyers, C. L. The phosphatidylinositol 3-kinase-akt Pathway in human cancer. Nat. Rev. Cancer, 2: 489-501, 2002.